Interactions with Microbial Proteins Driving the Antibacterial Activity of Flavonoids
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Metabolic Engineering of Microbial Cell Factories for Biosynthesis of Flavonoids: a Review
molecules Review Metabolic Engineering of Microbial Cell Factories for Biosynthesis of Flavonoids: A Review Hanghang Lou 1,†, Lifei Hu 2,†, Hongyun Lu 1, Tianyu Wei 1 and Qihe Chen 1,* 1 Department of Food Science and Nutrition, Zhejiang University, Hangzhou 310058, China; [email protected] (H.L.); [email protected] (H.L.); [email protected] (T.W.) 2 Hubei Key Lab of Quality and Safety of Traditional Chinese Medicine & Health Food, Huangshi 435100, China; [email protected] * Correspondence: [email protected]; Tel.: +86-0571-8698-4316 † These authors are equally to this manuscript. Abstract: Flavonoids belong to a class of plant secondary metabolites that have a polyphenol structure. Flavonoids show extensive biological activity, such as antioxidative, anti-inflammatory, anti-mutagenic, anti-cancer, and antibacterial properties, so they are widely used in the food, phar- maceutical, and nutraceutical industries. However, traditional sources of flavonoids are no longer sufficient to meet current demands. In recent years, with the clarification of the biosynthetic pathway of flavonoids and the development of synthetic biology, it has become possible to use synthetic metabolic engineering methods with microorganisms as hosts to produce flavonoids. This article mainly reviews the biosynthetic pathways of flavonoids and the development of microbial expression systems for the production of flavonoids in order to provide a useful reference for further research on synthetic metabolic engineering of flavonoids. Meanwhile, the application of co-culture systems in the biosynthesis of flavonoids is emphasized in this review. Citation: Lou, H.; Hu, L.; Lu, H.; Wei, Keywords: flavonoids; metabolic engineering; co-culture system; biosynthesis; microbial cell factories T.; Chen, Q. -
Thesis of Potentially Sweet Dihydrochalcone Glycosides
University of Bath PHD The synthesis of potentially sweet dihydrochalcone glycosides. Noble, Christopher Michael Award date: 1974 Awarding institution: University of Bath Link to publication Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 05. Oct. 2021 THE SYNTHESIS OF POTBTTIALLY SWEET DIHYDROCHALCOITB GLYCOSIDES submitted by CHRISTOPHER MICHAEL NOBLE for the degree of Doctor of Philosophy of the University of Bath. 1974 COPYRIGHT Attention is drawn to the fact that copyright of this thesis rests with its author.This copy of the the sis has been supplied on condition that anyone who con sults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be pub lished without the prior written consent of the author. -
Chemistry and Pharmacology of Kinkéliba (Combretum
CHEMISTRY AND PHARMACOLOGY OF KINKÉLIBA (COMBRETUM MICRANTHUM), A WEST AFRICAN MEDICINAL PLANT By CARA RENAE WELCH A Dissertation submitted to the Graduate School-New Brunswick Rutgers, The State University of New Jersey in partial fulfillment of the requirements for the degree of Doctor of Philosophy Graduate Program in Medicinal Chemistry written under the direction of Dr. James E. Simon and approved by ______________________________ ______________________________ ______________________________ ______________________________ New Brunswick, New Jersey January, 2010 ABSTRACT OF THE DISSERTATION Chemistry and Pharmacology of Kinkéliba (Combretum micranthum), a West African Medicinal Plant by CARA RENAE WELCH Dissertation Director: James E. Simon Kinkéliba (Combretum micranthum, Fam. Combretaceae) is an undomesticated shrub species of western Africa and is one of the most popular traditional bush teas of Senegal. The herbal beverage is traditionally used for weight loss, digestion, as a diuretic and mild antibiotic, and to relieve pain. The fresh leaves are used to treat malarial fever. Leaf extracts, the most biologically active plant tissue relative to stem, bark and roots, were screened for antioxidant capacity, measuring the removal of a radical by UV/VIS spectrophotometry, anti-inflammatory activity, measuring inducible nitric oxide synthase (iNOS) in RAW 264.7 macrophage cells, and glucose-lowering activity, measuring phosphoenolpyruvate carboxykinase (PEPCK) mRNA expression in an H4IIE rat hepatoma cell line. Radical oxygen scavenging activity, or antioxidant capacity, was utilized for initially directing the fractionation; highlighted subfractions and isolated compounds were subsequently tested for anti-inflammatory and glucose-lowering activities. The ethyl acetate and n-butanol fractions of the crude leaf extract were fractionated leading to the isolation and identification of a number of polyphenolic ii compounds. -
Chromanone-A Prerogative Therapeutic Scaffold: an Overview
Arabian Journal for Science and Engineering https://doi.org/10.1007/s13369-021-05858-3 REVIEW-CHEMISTRY Chromanone‑A Prerogative Therapeutic Scafold: An Overview Sonia Kamboj1,2 · Randhir Singh1 Received: 28 September 2020 / Accepted: 9 June 2021 © King Fahd University of Petroleum & Minerals 2021 Abstract Chromanone or Chroman-4-one is the most important and interesting heterobicyclic compound and acts as a building block in medicinal chemistry for isolation, designing and synthesis of novel lead compounds. Structurally, absence of a double bond in chromanone between C-2 and C-3 shows a minor diference from chromone but exhibits signifcant variations in biological activities. In the present review, various studies published on synthesis, pharmacological evaluation on chroman- 4-one analogues are addressed to signify the importance of chromanone as a versatile scafold exhibiting a wide range of pharmacological activities. But, due to poor yield in the case of chemical synthesis and expensive isolation procedure from natural compounds, more studies are required to provide the most efective and cost-efective methods to synthesize novel chromanone analogs to give leads to chemistry community. Considering the versatility of chromanone, this review is designed to impart comprehensive, critical and authoritative information about chromanone template in drug designing and development. Keywords Chroman-4-one · Chromone · Pharmacological activity · Synthesis · Analogues 1 Introduction dihydropyran (ring B) which relates to chromane, chromene, chromone and chromenone, but the absence of C2-C3 dou- Chroman-4-one is one of the most important heterobicyclic ble bond of chroman-4-one skeleton makes a minor difer- moieties existing in natural compounds as polyphenols and ence (Table 1) from chromone and associated with diverse as synthetic compounds like Taxifolin, also known as chro- biological activities [1]. -
Supplementary Materials Evodiamine Inhibits Both Stem Cell and Non-Stem
Supplementary materials Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70 Seung Yeob Hyun, Huong Thuy Le, Hye-Young Min, Honglan Pei, Yijae Lim, Injae Song, Yen T. K. Nguyen, Suckchang Hong, Byung Woo Han, Ho-Young Lee - 1 - Table S1. Short tandem repeat (STR) DNA profiles for human cancer cell lines used in this study. MDA-MB-231 Marker H1299 H460 A549 HCT116 (MDA231) Amelogenin XX XY XY XX XX D8S1179 10, 13 12 13, 14 10, 14, 15 13 D21S11 32.2 30 29 29, 30 30, 33.2 D7S820 10 9, 12 8, 11 11, 12 8 CSF1PO 12 11, 12 10, 12 7, 10 12, 13 D3S1358 17 15, 18 16 12, 16, 17 16 TH01 6, 9.3 9.3 8, 9.3 8, 9 7, 9.3 D13S317 12 13 11 10, 12 13 D16S539 12, 13 9 11, 12 11, 13 12 D2S1338 23, 24 17, 25 24 16 21 D19S433 14 14 13 11, 12 11, 14 vWA 16, 18 17 14 17, 22 15 TPOX 8 8 8, 11 8, 9 8, 9 D18S51 16 13, 15 14, 17 15, 17 11, 16 D5S818 11 9, 10 11 10, 11 12 FGA 20 21, 23 23 18, 23 22, 23 - 2 - Table S2. Antibodies used in this study. Catalogue Target Vendor Clone Dilution ratio Application1) Number 1:1000 (WB) ADI-SPA- 1:50 (IHC) HSP70 Enzo C92F3A-5 WB, IHC, IF, IP 810-F 1:50 (IF) 1 :1000 (IP) ADI-SPA- HSP90 Enzo 9D2 1:1000 WB 840-F 1:1000 (WB) Oct4 Abcam ab19857 WB, IF 1:100 (IF) Nanog Cell Signaling 4903S D73G4 1:1000 WB Sox2 Abcam ab97959 1:1000 WB ADI-SRA- Hop Enzo DS14F5 1:1000 WB 1500-F HIF-1α BD 610958 54/HIF-1α 1:1000 WB pAkt (S473) Cell Signaling 4060S D9E 1:1000 WB Akt Cell Signaling 9272S 1:1000 WB pMEK Cell Signaling 9121S 1:1000 WB (S217/221) MEK Cell Signaling 9122S 1:1000 -
Chemical Profiles and Simultaneous Quantification of Aurantii Fructus By
molecules Article Chemical Profiles and Simultaneous Quantification of Aurantii fructus by Use of HPLC-Q-TOF-MS Combined with GC-MS and HPLC Methods Yingjie He 1,2,† ID , Zongkai Li 3,†, Wei Wang 2, Suren R. Sooranna 4 ID , Yiting Shi 2, Yun Chen 2, Changqiao Wu 2, Jianguo Zeng 1,2, Qi Tang 1,2,* and Hongqi Xie 1,2,* 1 Hunan Key Laboratory of Traditional Chinese Veterinary Medicine, Hunan Agricultural University, Changsha 410128, China; [email protected] (Y.H.); [email protected] (J.Z.) 2 National and Local Union Engineering Research Center for the Veterinary Herbal Medicine Resources and Initiative, Hunan Agricultural University, Changsha 410128, China; [email protected] (W.W.); [email protected] (Y.S.); [email protected] (Y.C.); [email protected] (C.W.) 3 School of Medicine, Guangxi University of Science and Technology, Liuzhou 565006, China; [email protected] 4 Department of Surgery and Cancer, Chelsea and Westminster Hospital, Imperial College London, London SW10 9NH, UK; [email protected] * Correspondence: [email protected] (Q.T.); [email protected] (H.X.); Fax: +86-0731-8461-5293 (H.X.) † These authors contributed equally to this work. Received: 1 August 2018; Accepted: 29 August 2018; Published: 30 August 2018 Abstract: Aurantii fructus (AF) is a traditional Chinese medicine that has been used to improve gastrointestinal motility disorders for over a thousand years, but there is no exhaustive identification of the basic chemical components and comprehensive quality control of this herb. In this study, high-performance liquid chromatography coupled with quadrupole time of flight mass spectrometry (HPLC-Q-TOF-MS) and gas chromatography coupled mass spectrometry (GC-MS) were employed to identify the basic chemical compounds, and high-performance liquid chromatography (HPLC) was developed to determine the major biochemical markers from AF extract. -
Chondroprotective Agents
Europaisches Patentamt J European Patent Office © Publication number: 0 633 022 A2 Office europeen des brevets EUROPEAN PATENT APPLICATION © Application number: 94109872.5 © Int. CI.6: A61K 31/365, A61 K 31/70 @ Date of filing: 27.06.94 © Priority: 09.07.93 JP 194182/93 Saitama 350-02 (JP) Inventor: Niimura, Koichi @ Date of publication of application: Rune Warabi 1-718, 11.01.95 Bulletin 95/02 1-17-30, Chuo Warabi-shi, 0 Designated Contracting States: Saitama 335 (JP) CH DE FR GB IT LI SE Inventor: Umekawa, Kiyonori 5-4-309, Mihama © Applicant: KUREHA CHEMICAL INDUSTRY CO., Urayasu-shi, LTD. Chiba 279 (JP) 9-11, Horidome-cho, 1-chome Nihonbashi Chuo-ku © Representative: Minderop, Ralph H. Dr. rer.nat. Tokyo 103 (JP) et al Cohausz & Florack @ Inventor: Watanabe, Koju Patentanwalte 2-5-7, Tsurumai Bergiusstrasse 2 b Sakado-shi, D-30655 Hannover (DE) © Chondroprotective agents. © A chondroprotective agent comprising a flavonoid compound of the general formula (I): (I) CM < CM CM wherein R1 to R9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof, or a naturally occurring glycoside thereof is disclosed. The 00 00 above compound strongly inhibits proteoglycan depletion from the chondrocyte matrix and exhibits a function to (Q protect cartilage, and thus, is extremely effective for the treatment of arthropathy. Rank Xerox (UK) Business Services (3. 10/3.09/3.3.4) EP 0 633 022 A2 BACKGROUND OF THE INVENTION 1 . Field of the Invention 5 The present invention relates to an agent for protecting cartilage, i.e., a chondroprotective agent, more particularly, a chondroprotective agent containing a flavonoid compound or a stereoisomer thereof, or a naturally occurring glycoside thereof. -
WO 2017/050853 Al 30 March 2017 (30.03.2017) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/050853 Al 30 March 2017 (30.03.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12P 19/44 (2006.01) C12N 15/52 (2006.01) kind of national protection available): AE, AG, AL, AM, C12P 17/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP20 16/072474 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 2 1 September 2016 (21 .09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/222,919 24 September 2015 (24.09.2015) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: EVOLVA SA [CH/CH]; Duggingerstrasse 23, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 4153 Reinach (CH). -
EEE M W 24B 24A 27B 27A N Patent Application Publication Dec
US 2009031 1494A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0311494 A1 YAMASHTA et al. (43) Pub. Date: Dec. 17, 2009 (54) RELIEF PRINTING PLATE PRECURSOR FOR (30) Foreign Application Priority Data LASER ENGRAVING, RELIEF PRINTING PLATE, AND PROCESS FOR PRODUCING Jun. 17, 2008 (JP) ................................. 2008-157907 RELEF PRINTING PLATE Feb. 10, 2009 (JP) ................................. 2009-028816 (75) Inventors: Masako YAMASHITA, Publication Classification Shizuoka-ken (JP); Atsushi (51) Int. Cl. SUGASAKI, Shizuoka-ken (JP) B32B 3/00 (2006.01) Correspondence Address: GO3F 7/20 (2006.01) Moss & Burke, PLLC GO3F 7/004 (2006.01) 401 Holland Lane, Suite 407 Alexandria, VA 22314 (US) (52) U.S. Cl. .................... 428/195.1: 430/306: 430/286.1 (73) Assignee: FUJIFILM CORPORATION, (57) ABSTRACT Tokyo (JP) A relief printing plate precursor for laser engraving, including (21) Appl. No.: 12/476,260 a relief forming layer containing (A) a polymerizable com pound having an ethylenic unsaturated bond. (B) a binder (22) Filed: Jun. 2, 2009 polymer, and (C) a compound having deodorizing ability. 11 50 FA - 42 SUB SCANNING DIRECTION -10 - 228 7.s 55 21B EEE m w 24B 24A 27B 27A N Patent Application Publication Dec. 17, 2009 US 2009/0311494 A1 F.G. 1 FA SCANNING DIRECTION 7OA a. CSy ra & 5A - 27WSNS AD 23Ar S3EEASEE21 E-25sagaa EEEEEEEEEEEEEEEEEEEEEEEEE-22s awslighlights fskillsw. 21B 2 TTT "TT". US 2009/031 1494 A1 Dec. 17, 2009 RELEF PRINTING PLATE PRECURSORFOR mask to develop and remove an uncured area, and there is LASER ENGRAVING, RELIEF PRINTING room for improvement since development treatment is nec PLATE, AND PROCESS FOR PRODUCING essary. -
Evaluation of Anticancer Activities of Phenolic Compounds In
EVALUATION OF ANTICANCER ACTIVITIES OF PHENOLIC COMPOUNDS IN BLUEBERRIES AND MUSCADINE GRAPES by WEIGUANG YI (Under the Direction of CASIMIR C. AKOH) ABSTRACT Research has shown that diets rich in phenolic compounds may be associated with lower risk of several chronic diseases including cancer. This study systematically evaluated the bioactivities of phenolic compounds in blueberries and muscadine grapes, and assessed their potential cell growth inhibition and apoptosis induction effects using two colon cancer cell lines (HT-29 and Caco-2), and one liver cancer cell line (HepG2). In addition, the absorption of blueberry anthocyanin extracts was evaluated using Caco-2 human intestinal cell monolayers. Polyphenols in three blueberry cultivars (Briteblue, Tifblue and Powderblue), and four cultivars of muscadine (Carlos, Ison, Noble, and Supreme) were extracted and freeze dried. The extracts were further separated into phenolic acids, tannins, flavonols, and anthocyanins using a HLB cartridge and LH20 column. In both blueberries and muscadine grapes, some individual phenolic acids and flavonoids were identified by HPLC with more than 90% purity in anthocyanin fractions. The dried extracts and fractions were added to the cell culture medium to test for cell growth inhibition and induction of apoptosis. Polyphenols from both blueberries and muscadine grapes had significant inhibitory effects on cancer cell growth. The phenolic acid fraction showed relatively lower bioactivities with 50% inhibition at 0.5-3 µg/mL. The intermediate bioactivities were observed in the flavonol and tannin fractions. The greatest inhibitory effect among all four fractions was from the anthocyanin fractions in the three cell lines. Cell growth was significantly inhibited more than 50% by the anthocyanin fractions at concentrations of 15-300 µg/mL. -
W O 2014/006097 a L 9 January 2014 (09.01.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2014/006097 A l 9 January 2014 (09.01.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A01N 43/16 (2006.01) A01N 65/36 (2009.01) kind of national protection available): AE, AG, AL, AM, A61K 8/49 (2006.01) A01P 1/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/352 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, PCT/EP20 13/064042 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 3 July 20 13 (03.07.2013) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 12174837.0 3 July 2012 (03.07.2012) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: CEBEC GROUP LTD. -
ABSTRACT YUZUAK, SEYIT. Utilizing Metabolomics and Model Systems
ABSTRACT YUZUAK, SEYIT. Utilizing Metabolomics and Model Systems to Gain Insight into Precursors and Polymerization of Proanthocyanidins in Plants (Under the direction of Dr. De-Yu Xie). Proanthocyanidins (PAs) are oligomers or polymers of flavan-3-ols. In plants, PAs have multiple protective functions against biotic and abiotic stresses. PAs are also important nutraceuticals existing in common beverages and food products to benefit human health. To date, although the biosynthesis of PAs has been intensively studieed and fundamental progress has been made in over the past decades, many questions remain unanswered. For example, its direct precursors of extension units are unknown and their monomer structure diversity are also unclear. These questions about proanthocyanidins result from not having of model systems and effective technologies. Our laboratory has made significant progress in enhancing the understanding of these unknown and unclear points regarding proanthocyanidins. In my dissertation research reported here, I focus on two areas: testing muscadine as a crop system to develop metabolomics for studying precursor diversity and isolating enzymes from a red cell tobacco system to understand the precursors of the extension units of PA. First, I developed a metabolomics protocol to analyze anthocyanidins and anthocyanins in muscadine grape. This study demonstrated that muscadine berries can produce at least six anthocyanidins, revealing the diversity of pathway precursors for PAs. The Journal of Agriculture and Food Chemistry is reviewing this work. Second, I developed a metabolomics protocol of HPLC-qTOF-MS/MS to analyze flavan- 3-ols and dimeric PAs in muscadine grape. This study also demonstrated the high structure diversity of flavan-3-ols, particularly methylated flavan-3-ols.